Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background And Purpose: Molecular glioblastomas are challenging to distinguish from lower-grade diffuse astrocytomas (grades 2-3) without T2/T2 FLAIR mismatch, when assessed on T1-gadolinium and T2/T2 FLAIR MRI. This study aimed to evaluate the performance of the ADC from diffusion-weighted imaging and the relative CBV from DSC perfusion imaging in differentiating molecular glioblastomas from lower-grade diffuse astrocytomas.

Materials And Methods: Fourteen patients with molecular glioblastomas (defined as isocitrate dehydrogenase wildtype (IDH-wt), exhibiting one or more of the following: telomerase reverse transcriptase (TERT) promoter mutation, epidermal growth factor receptor (EGFR) gene amplification, or +7/-10 chromosomal alterations, but without microvascular proliferation or necrosis) and thirteen patients with lower-grade diffuse astrocytomas (IDH-mutated or not elsewhere classified, grades 2-3) were included. ADC values and DSC-rCBV values were measured, and the two groups were compared using T‑test and Wilcoxon rank-sum test. Combinations of variables and tumor characteristics were analyzed using binary logistic regression, receiver operating curve (ROC) analysis, and Firth regression model.

Results: Molecular glioblastomas exhibited lower minimum ADC, mean ADC (p < 0.01), maximum ADC (p < 0.05) and higher standard deviation of ADC (p < 0.05), compared to lower-grade astrocytomas, measured in a 7 mm ROI in the lowest ADC region. Molecular glioblastoma also had higher normalized median, average, and minimum rCBV ratios (p < 0.01) in a 10 mm ROI in the highest perfused region. A combined receiver operating curve (ROC) model of ADC and rCBV achieved an area under the curve (AUC) of 0.93 (95% CI: 0.82-1.00).

Conclusions: This study demonstrates that ADC and rCBV measurements can help differentiate molecular glioblastomas from lower-grade diffuse astrocytomas lacking T2/T2 FLAIR mismatch. These findings may aid in preoperative tumor characterization, surgical planning, and prognosis.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00062-025-01550-3DOI Listing

Publication Analysis

Top Keywords

molecular glioblastomas
20
lower-grade diffuse
16
diffuse astrocytomas
12
glioblastomas lower-grade
8
grades 2-3
8
t2/t2 flair
8
glioblastomas
5
differentiation molecular
4
lower-grade
4
diffuse
4

Similar Publications

Comparative efficacy and safety of therapeutic strategies for EGFRvIII positive recurrent glioblastoma.

iScience

September 2025

Beijing Institute of Brain Disorders, Laboratory of Brain Disorders, Ministry of Science and Technology, Collaborative Innovation Center for Brain Disorders, Capital Medical University, No.10 Xitoutiao You'anmenwai Fengtai District, Beijing 100069, P.R. China.

Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor, and EGFRvIII mutation has been associated with treatment resistance and poor prognosis, highlighting the need for more effective therapeutic strategies. We conducted a random-effects Bayesian network meta-analysis to compare the efficacy and safety of treatments for EGFRvIII-positive recurrent GBM (rGBM), evaluating overall survival (OS), progression-free survival (PFS), and objective response rate (ORR). Seven clinical trials were included ( = 716).

View Article and Find Full Text PDF

Background: Glioblastoma (GBM) is an extremely aggressive brain tumor, marked by restricted therapeutic possibilities and a generally unfavorable prognosis. GBM's complexity and heterogeneity necessitate comprehensive genetic and immunological profiling to enhance therapeutic strategies.

Methods: The study integrated The Cancer Genome Atlas (TCGA) and Integrative Epidemiology Unit Open Genome-Wide Association Studies (IEU OpenGWAS) data to identify genetic factors influencing GBM using expression quantitative trait loci (eQTL) and genome-wide association studies (GWAS).

View Article and Find Full Text PDF

Glioblastoma (GB), IDH-wildtype (IDH-wt), is the most prevalent primary malignant brain neoplasm in adults. Despite adjuvant therapy, the prognosis for these tumors remains dismal, with a median survival of around 15-18 months. Although rare, extracranial metastases from GB are reported with increasing frequency, likely due to advancements in follow-up, treatments, and improved patient survival.

View Article and Find Full Text PDF

One of the key factors contributing to the poor prognosis of glioblastoma is the treatment resistance of glioma stem cells (GSCs). In this study, the efficacy of photodynamic therapy (PDT) using talaporfin sodium (NPe6), a second-generation photosensitizer, in combination with a semiconductor laser approved for clinical use in Japan was evaluated. The evaluation was performed in a patient-derived glioma stem cell (GSC) line, MGG8, which was established from human glioblastoma tissue.

View Article and Find Full Text PDF

Novel Thioredoxin reductase 1 inhibitor BS1801 relieves treatment resistance and triggers endoplasmic reticulum stress by elevating reactive oxygen species in glioma.

Redox Biol

August 2025

Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, No.119 South 4th Ring Road West, Beijing, China; Chinese Glioma Genome Atlas Network (CGGA) and Asian Glioma Genome Atlas Network (AGGA), Beijing, China; Beijing Engineering Research Center of Target

Glioma patients will inevitably develop resistance to temozolomide (TMZ) leading to tumor recurrence. By comparing genomic differences between primary and recurrent glioma patients, Thioredoxin reductase 1 (TrxR1) was identified as a crucial role in TMZ resistance. Glioma cells elevate the expression level of TXNRD1 to against TMZ-induced reactive oxygen species (ROS), thereby conferring TMZ resistance.

View Article and Find Full Text PDF